<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01896323</url>
  </required_header>
  <id_info>
    <org_study_id>CC-223-CP-003</org_study_id>
    <nct_id>NCT01896323</nct_id>
  </id_info>
  <brief_title>CC-223 and Ketoconazole Drug-Drug Interaction Study</brief_title>
  <official_title>An Open-Label, Two-Period, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Single Dose Pharmacokinetics of CC-223 in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center open-label study to compare how CC-223 (the study drug being
      investigated) interacts with the drug ketoconazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 2 period study, which lasts about 6 weeks long. About 14 males will be entered into
      the study, during which they will receive the study drug (a single dose of 20 mg CC-223) 400
      mg ketoconazole.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 96 hours post dose</time_frame>
    <description>AUC-area under the plasma concentration-time curve;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 96 hours post dose</time_frame>
    <description>Cmax-maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 96 hours post dose</time_frame>
    <description>Tmax - Time to maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>up to 96 hours post dose</time_frame>
    <description>t½ - terminal elimination half-life in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 28 days after last dose of study drug</time_frame>
    <description>Number of subjects with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CC-223</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketokonazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketoconazole administration on study days 1 through 8 of Period 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-223</intervention_name>
    <description>CC-223 20 mg tablets</description>
    <arm_group_label>CC-223</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketoconazole</intervention_name>
    <description>Ketoconazole 400 mg tablets</description>
    <arm_group_label>Ketokonazole</arm_group_label>
    <other_name>Nizoral</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must understand and voluntarily sign a written informed consent form before
             participation.

          2. Must be able to communicate with the study doctor, understand and comply with the
             requirements of the study, and agree to adhere to restrictions and examination
             schedules.

          3. Healthy male subject of any race between 18 to 65 years of age, and in good health as
             determined by a physical examination.

             - For males: Agree to use barrier contraception not made of natural (animal) membrane
             (for example, latex or polyurethane condoms are acceptable) when engaging in sexual
             activity with a female of child-bearing potential while on study medication, and for
             at least 28 days after the last dose of study medication.

          4. Must have a body mass index between 18 and 33 kilograms/meter squared.

          5. Clinical laboratory tests must be within normal limits or acceptable to the study
             doctor.

          6. Must not have a fever, with a blood pressure between 90/50 to 140/90 millimeters of
             mercury, and pulse rate: between 40 to 110 beats per minute.

          7. Must have a normal or clinically acceptable 12-lead electrocardiogram.

        Exclusion Criteria:

          1. History of any clinically significant and relevant neurological, gastrointestinal,
             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,
             hematological, allergic disease, drug allergies, or other major disorders.

          2. Any condition which places the subject at unacceptable risk if he were to participate
             in the study, or confounds the ability to interpret data from the study.

          3. Used any prescribed or topical medication within one month before the first dose of
             study drug, unless consultation between the sponsor and the study doctor.

          4. Used any non-prescribed systemic or topical medication (including vitamin/mineral
             supplements, and herbal medicines) within 2 weeks (30 days for St. John's Wort®) of
             the first dose administration, unless sponsor agreement is obtained.

          5. Has any surgical or medical conditions possibly affecting drug absorption,
             distribution, metabolism and excretion of the study drug, for example, bariatric
             procedure.

          6. Donated blood or plasma within 2 months before the first dose of study drug.

          7. History of drug abuse within 2 years before dosing, or a positive drug screening test
             reflecting consumption of illicit drugs.

          8. History of alcohol abuse within 2 years before dosing, or positive alcohol screen.

          9. Known to have serum hepatitis or known to be a carrier of the hepatitis B surface
             antigen, or hepatitis C antibody, or have a positive result to the test for Human
             Immune virus antibodies at Screening.

         10. Exposed to an investigational drug within one month 30 days before the first dose of
             study drug.

         11. Smoke more than 10 cigarettes per day, or the equivalent in other tobacco products.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward O'Mara, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2013</study_first_posted>
  <last_update_submitted>April 3, 2014</last_update_submitted>
  <last_update_submitted_qc>April 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketoconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

